In response to an increasing number of projects, notably in oncology, Indian CRDMO Sai Life Sciences, has opened a 1,485 m² high potency API (HPAPI) facility at its cGMP API campus in Bidar. This follows on from the opening of an HPAPI development facility at the Hyderabad R&D campus.

The company said that this expands its expertise “across HPAPI development and manufacturing, providing its customers with a streamlined pathway for NCE development”. It will now be able to handle all aspects of the product life cycle.